CEO
AP
Amporin Pharmaceuticals
Amporin Pharmaceuticals AG is developing a new class of small molecule drugs that protect and repair cell membranes, targeting the underlying molecular processes of degenerative diseases caused by protein misfolding, such as Alzheimer's and Parkinson's. This approach aims to provide the first oral disease-modifying treatments for over 50 degenerative diseases affecting more than half a billion people globally.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
CHF 40KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $45.2Kacross 1 round
CHF 40K · Seed
Announced Dec 2023
Disclosed cumulative: $45.2K
RoundDateAmountValuationInvestors
Founders
Product
Problem
Many degenerative diseases, such as Alzheimer's and Parkinson's, are caused by protein misfolding, which damages cell membranes. Current treatments do not address the underlying molecular processes of these diseases.
Solution
Amporin Pharmaceuticals AG is developing a novel class of small molecule drugs designed to protect and repair cell membranes. By targeting the molecular processes of degenerative diseases caused by protein misfolding, Amporin aims to provide disease-modifying treatments. These treatments are intended to be administered orally, offering a convenient therapeutic option for patients. The company's approach has the potential to address over 50 degenerative diseases, impacting a significant portion of the global population.
Target Audience
The primary target audience includes individuals suffering from degenerative diseases caused by protein misfolding, such as Alzheimer's and Parkinson's, and the healthcare providers who treat them.
Features
- Small molecule drugs designed for oral administration
- Targets protein misfolding, a key factor in degenerative diseases
- Protects and repairs cell membranes at the molecular level
- Potential application for over 50 degenerative diseases